Research Summary
iDegLira improves glycemic control in type 2 diabetes
Moderate confidence
Low bias
Last updated June 15, 2026Key Takeaway:
Switching from premixed insulin to the insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) improved glycemic control in participants with type 2 diabetes.
Study at a Glance
Participants
Intervention
Insulin glargine/lixisenatide fixed-ratio combination (iDegLira)
Outcomes
HbA1c, Time in range (TIR), Fasting blood sugar (FBS), Total daily insulin dose, Body weight, Diabetes-related misconceptions
Funding
Non-Industry Sponsored
Save this study and add notes to your research library.
Main Effects
HbA1c decreased from 7.39% to 7.10% (p=0.045)
Average fasting glucose decreased from 8.25 mmol/L to 6.92 mmol/L (p<0.031)
Total daily insulin dose decreased from 44.5 units/day to 23.1 units/day (p<0.001)
Body weight decreased from 86.5 kg to 84.5 kg (p<0.001)
Evidence Summary
| Intervention | Outcome | Measured Change | Study Effect |
|---|---|---|---|
 Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) (Medications) |  Body weight (Weight & Anthropometrics) | Decrease | Strong |
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) (Medications) |  Diabetes-related misconceptions (Patient-Reported) | No Change | Unclear |
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) (Medications) |  Fasting blood sugar (FBS) (Glycemic Control) | Decrease | Strong |
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) (Medications) | HbA1c (Glycemic Control) | Decrease | Strong |
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) (Medications) | Time in range (Glycemic Control) | Increase | Strong |
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) (Medications) | Total daily insulin dose (Glycemic Control) | Decrease | Strong |
Unlock Full Evidence Analysis
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
Evidence Suggest
- HbA1c reduction of 0.29% (p=0.045) indicates improved glycemic control.
- Average fasting glucose decreased by 1.33 mmol/L (p=0.031).
- Total daily insulin dose reduced by 21 units/day (p<0.001).
Who this applies to
- Adults diagnosed with type 2 diabetes.
- Patients currently using premixed insulin.
- Individuals seeking improved glycemic control.
Keep in Mind
- Findings are based on a cohort study without a control group.
- Results may vary based on individual patient characteristics.
- Further studies are needed to confirm long-term benefits.
Between the Lines
- Single-arm study design limits comparison with a control group.
- Results may not be generalizable to all populations with type 2 diabetes.
- Lack of long-term follow-up data to assess sustained effects.
Unlock Full Analysis
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Already have an account?
Journal Reference
Nika AKT, Andrijana K, Mitja K. Switching from Premixed Insulin to iDegLira Improves Glycemic Control in Type 2 Diabetes. Frontiers in Endocrinology. 2025;16:1715800. doi:10.3389/fendo.2025.1715800
Connected Evidence
Discover how this study fits into the broader diabetes evidence landscape.
This study contributes to evidence on Insulin Therapies and Total daily insulin dose, Insulin Therapies and Body Weight.
Related evidence relationships
Explore in Evidence ArchiveThis study contributes to the evidence on the following intervention–outcome relationships.
Included in these evidence collections
Curated evidence collections and hubs this study is part of.
Insulin Therapies Evidence Hub
All studies on Insulin Therapies
2 studies
intervention_hubContributes to Insulin Therapies evidence base.
Total daily insulin dose Evidence Hub
All studies measuring Total daily insulin dose
2 studies
outcome_hubMeasures Total daily insulin dose as a key outcome.
Body Weight Evidence Hub
All studies measuring Body Weight
1 studies
outcome_hubMeasures Body Weight as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in the evidence archive
Jump to pre-filtered views in the evidence archive.
All studies on Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) and Total daily insulin dose
Intervention: Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi)Outcome: Total daily insulin dose
2 results
All studies on Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) and Body weight
Intervention: Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi)Outcome: Body weight
1 results
All studies on Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi)
Intervention: Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi)
2 results
All studies measuring Total daily insulin dose
Outcome: Total daily insulin dose
2 results
All studies measuring Body weight
Outcome: Body weight
1 results
Questions this evidence helps answer
Key clinical and research questions this study contributes to.
Does insulin glargine/lixisenatide fixed-ratio combination (iglarlixi) improve Total daily insulin dose?
Based on connected evidence for Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) and Total daily insulin dose.
Does insulin glargine/lixisenatide fixed-ratio combination (iglarlixi) affect Body weight in people with diabetes?
Exploring evidence on Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) and Body weight outcomes.
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.